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Interest in evidence-based medicine (EBM) is growing in Italy, although its impact upon health policies 
and clinical practice is unclear. Rather 
than getting health information from 
unbiased evidence-based sources, 
doctors in Italy still rely heavily upon 
the pharmaceutical industry for their 
information needs. For example, a 
recent survey showed that general 
practitioners receive 11 visits per week 
by pharmaceutical sales representatives 
[1]. The study suggested that this 
information is considered complete 
and suffi ciently reliable by many 
doctors. 
In an effort to ensure that all 
physicians have access to valid and 
reliable evidence on drug effectiveness 
and safety, the Italian Drug Agency 
(AIFA) launched a program to 
disseminate independent and unbiased 
information. The agency did this 
by translating Clinical Evidence, a 
compendium of the best available 
evidence on treating a wide range 
of common conditions (Box 1), into 
Italian and distributing it freely. By 
2006, the fourth Italian edition (based 
on Clinical Evidence volume 14) had 
been published. The online Italian 
version of Clinical Evidence is freely 
available to all 248,000 doctors in 
practice in Italy.
In 1999, the fi rst free distribution of 
50,000 copies of Clinical Evidence was 
assessed through a survey exploring 
doctors’ judgement of its validity, 
relevance, and usability. Results 
showed that the compendium had 
been well received, and confi rmed 
doctors’ preference for problem-
driven information and the key role 
of a strong endorsement from health 
authorities for its implementation [2].
A compulsory system of continuing 
medical education (CME) for all 
health professionals was introduced 
in Italy in 1998, based on credits 
awarded for time spent on educational 
activities. The more traditional form of 
acquiring CME is to attend lectures and 
conferences; it is much more rare for 
doctors to be exposed to small group 
interactive events. In order to maximise 
the effectiveness of the fi nancial 
commitment for disseminating Clinical 
Evidence, and to speed up the diffusion 
of EBM, AIFA sponsored a free-access 
e-learning system, based on Clinical 
Evidence, called ECCE (the Italian 
acronym for Continuing Education 
Clinical Evidence).
ECCE: An e-Learning CME Program 
ECCE is an e-learning CME tool that 
uses interactive clinical vignettes based 
on chapters in Clinical Evidence and a 
predefi ned sequence of questions. The 
vignettes refl ect real-life circumstances 
as seen by an ordinary general 
practitioner in everyday practice. Whilst 
the primary target group of ECCE is 
general practitioners, many vignettes 
are also relevant to specialists.
Each vignette has a narrative with 
events presented in chronological 
order: the history evolves with new 
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Box 1. Clinical Evidence 
Clinical Evidence (http://www.
clinicalevidence.com) has specifi c 
features that make it different from 
both traditional textbooks and practice 
guidelines [19]: 
• Its contents are driven by practical 
questions rather than by the 
availability of evidence.
• It aims not to make recommendations 
but to inform based on the best 
available evidence.
• It highlights rather than hides gaps in 
research evidence.
• It is continuously updated. 
According to its Web site, Clinical 
Evidence “describes the best available 
evidence from systematic reviews, RCTs 
[randomised controlled trials], and 
observational studies where appropriate, 
and if there is no good evidence it says so.”
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insights from diagnostic tests or 
additional information reported by 
the patient. Users progress from step 
to step by overcoming a question/
answer decision system. Box 2 gives an 
example of a vignette from ECCE.
The response option includes one 
or more correct answers for each 
question, and other possible responses 
as distractors. Users gain credits 
upon completing all steps as long as 
they reach a score above 80% of the 
maximum total score. Vignettes provide 
one or two credits depending on the 
number of questions in the vignette. 
During the fi rst year we posted 120 
vignettes.
ECCE has all the standard advantages 
of e-learning. Users select what they 
wish to learn, when and at what pace. 
The system is easy to use and works with 
basic computer requirements (e.g., low 
speed connections). The contents of 
Clinical Evidence can be read on screen 
or printed and interactively managed 
along the steps of each vignette. The 
system tracks learning content and 
the learner’s progress. Eight vignettes 
translated in English are available at 
http:⁄⁄ecce-gb.fad-ecm.it (registration 
required).
ECCE became accessible to all 
physicians in March 2005 after a pilot 
period. Here we present the results of 
the fi rst year of usage (until February 
2006).
Doctors’ Use of ECCE 
In one year, 19,340 doctors voluntarily 
subscribed to ECCE (7.8% of all 
Italian practicing doctors) and 
around 93% logged in completing at 
least one vignette (Table 1). Almost 
one quarter (4,429, or 22.9%) were 
general practitioners (Table 2). The 
median age of the users was 50 years 
(interquartile range 40 to 56). Over 
half (52%) of users were based in rural 
areas, and there was regional variation 
in use: Sardinia had the highest rate 
of use (9.87% of all resident doctors) 
while Campania had the lowest 
(3.94%), and there was a modest 
north–south usage gradient (Figure 1). 
Doctors used ECCE throughout the 
entire day, with early morning and late 
evening being the most popular time 
slots. Altogether 215,412 vignettes have 
been completed and 292,058 credits 
awarded. The average number of 
completed vignettes for a single user 
was 13.75 (median 50, interquartile 
range 28–101), with a corresponding 
average credit of 16.22. There were 
3,468 doctors who obtained 25 or more 
credits (30.2% of those who acquired 
at least one credit), exceeding the 
mandatory ministerial requirement (24 
credits in 2005 for distance learning).
The top fi ve accessed vignettes 
were appendicitis, atrial fi brillation, 
herpes zoster, paracetamol poisoning, 
and acute low back pain. The easiest 
vignette to be solved had a success rate 
of 93.91% at fi rst attempt, while the 
average success rate was 79.19% and 
the hardest (“statistically advanced”) 
case had a 39.10% success rate. 
Mean time to interactively complete 
a vignette was nine minutes for one 
credit history and 18 minutes for two 
credit histories. Before completing 
the vignette, doctors are supposed to 
peruse the related chapter in Clinical 
Evidence (which is assumed to take fi ve 
minutes per page).
During the fi rst year the cost per 
credit supplied through ECCE was 
We present the fi rst step of the 
headache (chronic tension-type) vignette 
and the related question. The vignette 
was developed from the chapter 
Headache (chronic tension-type), in 
Clinical Evidence [20]. 
Margaret says to her family doctor: 
“This time I didn’t come for me, but 
to talk about Rachel, my 25-year-old 
daughter. As you probably remember, 
she got married last year; unfortunately, 
she doesn’t seem to get along well with 
her husband...Anyway, the other day 
she told me that in the past few months 
she has often suffered from headache; 
I’m quite worried about that, you know 
what I have been through...” The doctor 
remembers very well that many years 
before, Margaret, one of his fi rst patients, 
was always complaining about her 
headache, a pain that tormented her 
all the time and was not relieved by 
analgesics. He tells Margaret to come 
back with her daughter. After a few days 
the two women are in the doctor’s offi ce. 
Rachel says: “This headache is killing 
me. I have it every day now, sometimes 
with nausea. And I don’t want to take 
analgesics any more, they don’t do me 
any good”. She describes her pain as a 
bilateral, tight, “band-like” discomfort: 
“My head feels as if it is in a vice. 
Following the advice of a friend of mine 
I have also tried to take some drops of a 
benzodiazepine; but the headache didn’t 
go away, and I felt drowsy and light 
headed”. Rachel looks very pale, tired and 
tense. Examining her, the doctor doesn’t 
fi nd anything abnormal; he suspects 
a chronic tension-type headache, and 
prescribes a battery of blood tests.
Question: According to the studies 
identifi ed by Clinical Evidence, in Rachel’s 
case benzodiazepines:
• may be very effective, but only in the 
short term
• may be effective, but only in the long 
term
• may be useful only in people with very 
severe headache
• may induce a modest short term 
improvement, but are often associated 
with adverse effects
• are contraindicated
The correct answer is: In Rachel’s 
case, benzodiazepines may induce a 
modest short term improvement, but are 
often associated with adverse effects.
Box 2. Example of An ECCE Vignette
Table 1. Use of ECCE by Registered Doctors and Average Use by Single User
Aggregated Data, 
All Users
Mean Data, 
Single User
Total physicians registereda 19,340
Users logged inb 18,003 (93.1%)
Clinical vignettes undertaken 244,624 13.75
Clinical vignettes successfully completed 215,412 (88.1%) 12.13
Clinical vignettes successfully completed at fi rst attempt 170,969 (69.9%)
Total CME credits provided 292,058 16.22
aRegistered at 28 February 2006. 
bAt least one case attempted.
Total physicians in practice: 248,000; general practitioners: 47,000.
doi:10.1371/journal.pmed.0040113.t001
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2.4 Euros (including all direct costs: 
license to BMJ Publishing Group to 
reproduce Clinical Evidence, translation 
of the fourth edition into Italian, 
development of the e-learning 
CME system and its management 
and technological platform). The 
2.4 Euros excludes the costs of 
printing Clinical Evidence as well as 
indirect costs. All costs are tax free. 
Discounting the costs related to 
translation of Clinical Evidence and to 
the start-up of the platform, the cost 
per credit was 0.7 Euros.
Users’ Survey
At the end of each vignette doctors 
were asked—using an online 
questionnaire—to provide comments 
about their experience solving ECCE’s 
cases (75.1% response rate). ECCE’s 
vignettes were well received (Table 3): 
more than 90% of users considered 
them relevant and appropriate for 
educational purposes, and out of 
21,589 free-text feedback messages, 
17,902 (82.9%) were positive. 
Overall, these opinions were largely 
consistent with what emerged from 
three focus groups run in northern, 
southern, and central Italy. The 26 
clinicians who participated felt that 
ECCE was well representative of 
their clinical practice and that the 
information conveyed was reliable 
and relevant, despite the absence of 
evidence on how to make diagnoses 
(Clinical Evidence focuses on treatment, 
not diagnosis). The clinicians 
complained that reading the full 
chapter of Clinical Evidence was tedious, 
but appreciated the format of the 
clinical vignette, which allowed them to 
switch from passive reading to an active 
learning exercise. 
Discussion
The large number of subscribers 
to ECCE suggests that this CME 
programme is meeting an educational 
need. However, this number still 
represents only a small proportion 
(7.8%) of all practising doctors. But 
there has been limited promotion of 
ECCE, involving only a small number 
of medical journal adverts, and the 
program is still in its infancy. 
Limitations. This study has several 
limitations. The fi rst limitation is 
selection bias: there may have been 
an over-representation in our sample 
of doctors with a generally positive 
attitude toward EBM and with greater 
computer skills. ECCE has probably 
fi lled the gap that still exists between 
a growing demand for reliable and 
independent critical appraisal and a 
limited offering [3]. Thus the doctors 
in our survey could be classifi ed as 
early adopters of an evidence-based 
innovation and may have been 
different in key ways (i.e., having a 
positive perception of EBM) from the 
rest of Italian doctors [4]. 
A second limitation relates to the 
CME structural factor (i.e., mandatory 
requirement): we cannot rule out 
the possibility that some doctors 
intentionally used ECCE with the 
aim of collecting as many credits as 
possible. This “opportunistic use” 
was also highlighted during the focus 
groups. However, at least 30.2% of 
doctors exceeded the CME mandatory 
requirement, after which they were 
presumably using ECCE to challenge 
their own knowledge and competence. 
The last two limitations deal with the 
innovation itself (i.e., ECCE). Does the 
high success rate of the vignettes mean 
that ECCE was unable to discriminate 
poor performers from better ones? 
The average success rate was close to 
80% (considered a moderately easy 
test). The test discrimination capability 
could be biased towards middle 
achievers, an attribute which could be 
seen negatively. We think that this is 
not negative itself: innovations that are 
not diffi cult to do (low complexity) 
and easy to try (high trialability) 
maximise their perceived attraction 
and adoption [5]. 
A fourth limitation is that positive 
results may refl ect physician 
competence more than appropriate 
clinical practice. While changing 
provider behaviour could be seen as 
the fi nal step of the innovation decision 
process [6], it should be preceded 
by change in other dimensions, 
particularly knowledge [7,8]. If ECCE 
has any such effect, it infl uences 
knowledge and competency in using 
Table 2. Doctors’ Professional Profi les
Discipline n (%)
Internal medicine 5,614 (29.0)
General practice 4,429 (22.9)
Surgery 3,413 (17.6)
Paediatrics 1,017 (5.3)
Other (i.e., radiology, psychiatry, etc) 4,867 (25.2)
doi:10.1371/journal.pmed.0040113.t002
doi:10.1371/journal.pmed.0040113.g001
Figure 1. Doctors Using ECCE by Region
Red: urban areas; green: rural areas.
Table 3. Respondents’ Opinions about ECCE
Constructed Questions Yes, % (n)
Are ECCE’s vignettes:
Relevanta 93.6 (232,994)
Appropriate for educational purposesa 95.8 (232,994)
Free of commercial interestsa 84.5 (232,994)
Easy to usea 92.9 (150,231)
Have you received new information? 76.0 (152,965)
Do you intend to use this information in your practice? 93.3 (155,080)
Free Text Feedbacks (n = 21,589) % (n)
Positive 82.9 (17,902) 
Negative:
Content or software errors subsequently corrected 0.2% (35)
Reservations about CE’s sources or vignettes 6.2% (1,348)
Other criticisms 9.6% (2,073)
aResponses to these questions were dichotomised from an ordinal scale.
doi:10.1371/journal.pmed.0040113.t003
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EBM. While the recognition of the 
teaching properties of case histories 
is not new [9–11], in a recent study 
vignettes’ scores appeared to be highly 
correlated to physician practice in 
outpatient settings and were a valid 
overall measure of the process of care 
provided [12]. Furthermore, one of 
the greatest barriers to reading Clinical 
Evidence was boredom. The use of 
written case simulation seemed to 
transform the passive reading into a 
more interactive experience in which 
doctors searched for the right piece of 
information to be applied in specifi c 
situations.
The evidence-based innovation. 
AIFA supported the diffusion of 
Clinical Evidence, a user-friendly medical 
resource free of confl icts of interest. 
This approach is different from that 
of other countries, which supported, 
for example, free access to Cochrane 
systematic reviews [13]. Although the 
systematic reviews in Clinical Evidence 
and the Cochrane Library are related 
[14], Clinical Evidence was thought by 
policy makers to be more useful in 
daily practice by answering common 
and important clinical questions using 
clear summaries. Recognising the value 
of independent information, AIFA is 
attempting to balance a context where 
pharmaceutical companies have been 
the only information drivers for many 
years. The adoption of high quality 
information on EBM enhances doctors’ 
mastery of information, emphasising 
sources that are high in relevance and 
validity, and that do not require a huge 
amount of time to access [15].
In 2005 the cost for each 
credit provided through ECCE 
was less then 2.5 Euros. In 2006, 
maintaining the same patterns of 
usage, the estimated cost will be 0.7 
Euros/credit, a reasonable effort 
considering that in 2004 the average 
cost of each CME credit in Emilia-
Romagna, a region that monitored 
this expenditure, was 144.0 Euros 
[16]. Furthermore, this investment 
in independent information pales 
in comparison to the 3 billion Euros 
spent by pharmaceutical companies on 
marketing their drugs in Italy in 2004, 
an investment of about 8,000 Euros for 
each doctor [17]. 
Conclusion
Cultural and policy changes are 
brought about by a complex interaction 
of social, economic, and political 
factors, including the infl uence of 
thought leaders. In 2001 Smith and 
Chalmers wrote: “Universal free access 
to an integrated information resource 
built from the Cochrane Library, 
Clinical Evidence, and the metaRegister 
of Controlled Trials would go some way 
to reducing the inequities in access to 
information for improving health care” 
[18]. Italy is now starting to move in 
this direction. 
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